Back to top
more

Cocrystal Pharma (COCP)

(Delayed Data from NSDQ)

$1.73 USD

1.73
17,150

-0.04 (-2.26%)

Updated Nov 1, 2024 03:11 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Cocrystal Pharma, Inc. [COCP]

Reports for Purchase

Showing records 1 - 20 ( 36 total )

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

08/22/2024

Company Report

Pages: 5

Positive Pipeline Progress; 2Q24 Financials; Lowering PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

05/14/2024

Company Report

Pages: 4

1Q24 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

04/04/2024

Company Report

Pages: 4

Multiple Clinical Data Catalysts This Year; 2023 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

03/20/2024

Company Report

Pages: 5

CC-42344 FDA Feedback; KSURF Agreements Terminated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

01/03/2024

Company Report

Pages: 5

Merck Collaboration Terminated; Lowering PT to $10

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

12/13/2023

Company Report

Pages: 4

CC-42344 Phase 2a Trial Initiates Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

12/04/2023

Company Report

Pages: 4

CC-42344 Featured at World Vaccine Congress; 3Q23 Financials; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

11/03/2023

Company Report

Pages: 4

CC-42344 Phase 2a Influenza Program Gets UK Green Light; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

10/04/2023

Company Report

Pages: 4

CDI-988 Phase 1 Trial Subject Dosing Initiated; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

08/15/2023

Company Report

Pages: 4

2Q23 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

08/11/2023

Company Report

Pages: 4

Oral Protease Inhibitor Selected as Norovirus Lead Candidate; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

06/02/2023

Company Report

Pages: 4

CDI-988 Australian Trial Authorization Granted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

05/24/2023

Company Report

Pages: 6

Equity Raise Complete; 1Q23 Financials; Lowering PT to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

04/05/2023

Company Report

Pages: 5

Financial Results Reported; Favorable Judgment in Litigation; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

01/24/2023

Company Report

Pages: 5

CC-42344 Clinical Data Appears Favorable; Modulating PT to $35

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

12/05/2022

Company Report

Pages: 5

CC-42344 Showcased at World Antiviral Congress; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

12/01/2022

Company Report

Pages: 5

CC-42344 Influenza Candidate Shows Clinical Safety; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 18

11/07/2022

Company Report

Pages: 5

CC-42344 Influenza Agent Progress; Reverse Stock Split; Raising PT to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 19

08/23/2022

Company Report

Pages: 5

Antiviral Pipeline Progress; 2Q22 Financial Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Cocrystal Pharma, Inc.

Industry: Medical - Biomedical and Genetics

Record: 20

07/18/2022

Company Report

Pages: 5

Single Ascending Dose Portion of Phase 1 Trial Completed; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party
// eof